Cochlear-backed Epiminder ramps up US epilepsy study as cash runway stretches into 2028

Melbourne-based medical device company Epiminder (ASX: EPI) has reported accelerating momentum in its pivotal US reimbursement study for the Minder implantable EEG monitoring system, with 18 medical centres now contracted and 15 patients enrolled as the Cochlear-backed firm maintains a cash war…


Click here to view the original article.